Rhythm Pharmaceuticals to Present Virtually at Upcoming Investor Conference in June 2020

Rhythm Pharmaceuticals 将在2020年6月即将召开的投资者大会上正式亮相

2020-05-27 15:30:23 BioSpace

本文共1713个字,阅读需5分钟

BOSTON, May 26, 2020 -- Rhythm Pharmaceuticals, Inc. , a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that company management will participate in two investor conferences in June: Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020. Hunter Smith, Interim Chief Executive Officer and Chief Financial Officer, and Murray Stewart, M.D., Chief Medical Officer, will present a corporate overview at 3:00 p.m. ET. Goldman Sachs 41st Annual Global Healthcare Conference on Tuesday, June 9, 2020. Hunter Smith, Interim Chief Executive Officer and Chief Financial Officer, and Murray Stewart, M.D., Chief Medical Officer, will participate in a fireside chat at 3:50 p.m. ET. A live audio webcast of both presentations will be available under “Events & Presentations” in the Investor Relations section of the Company’s website at www.rhythmtx.com. A replay of the webcasts will be available on the Rhythm website for 30 days following the presentation. About Rhythm Rhythm is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity. In August 2019, the company announced positive topline results from pivotal Phase 3 clinical trials of setmelanotide, its MC4R agonist, in people living with POMC deficiency obesity and LEPR deficiency obesity and, in March 2020, completed its first rolling NDA submission to the FDA. Rhythm is also evaluating setmelanotide for reduction in hunger and body weight in a pivotal Phase 3 trial in people living with Bardet-Biedl and Alström syndromes, with topline data from this trial expected in the fourth quarter of 2020 or early in the first quarter of 2021. Rhythm is leveraging the Rhythm Engine -- comprised of its Phase 2 basket study, TEMPO Registry, GO-ID genotyping study and Uncovering Rare Obesity program -- to improve the understanding, diagnosis and potentially the treatment of rare genetic disorders of obesity. For healthcare professionals, visit www.UNcommonObesity.com for more information. For patients and caregivers, visit www.LEADforRareObesity.com for more information. The company is based in Boston, MA. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the potential, safety, efficacy, and regulatory and clinical progress of setmelanotide, the anticipated timing for release of topline clinical trial data, and participation in upcoming presentations and conferences. Statements using words such as “expect”, “anticipate”, “believe”, “may”, “will” and similar terms are also forward-looking statements. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the impact of our management transition, our ability to enroll patients in clinical trials, the design and outcome of clinical trials, the impact of competition, the ability to achieve or obtain necessary regulatory approvals, risks associated with data analysis and reporting, our liquidity and expenses, the impact of the COVID-19 pandemic on our business and operations, including our preclinical studies, clinical trials and commercialization prospects, and general economic conditions, and the other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020 and our other filings with the Securities and Exchange Commission. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise. Corporate Contact: David Connolly Head of Investor Relations and Corporate Communications Rhythm Pharmaceuticals, Inc. 857-264-4280 dconnolly@rhythmtx.com Investor Contact: Hannah Deresiewicz Stern Investor Relations, Inc. 212-362-1200 hannah.deresiewicz@sternir.com Media Contact: Adam Daley Berry & Company Public Relations 212-253-8881 adaley@berrypr.com
BOSTON ,2020年5月26日讯—— Rhythm Pharmaceuticals , Inc .,一家旨在开发和商业化治疗罕见基因肥胖症治疗疗法的后期生物制药公司,今天宣布公司管理层将于6月参加两次投资者会议: 杰富瑞虚拟医疗保健会议,星期二,2020年6月2日。 Hunter Smith ,临时首席执行官兼首席财务官,和 Murray Stewart ,医学医学博士(M.D.),首席医疗官,将在东部时间下午3点提交公司概况。 高盛全球医疗保健大会第41届,星期二,2020年6月9日。 临时首席执行官兼首席财务官 Hunter Smith 和医学医学博士(M.D.) Murray Stewart 将于东部时间下午3:50参加炉边谈话。 两个演示文稿的现场音频网络直播将在公司网站的投资者关系部分的“活动和演示”中提供,网址为 www.arturthx.com 。在演示文稿之后的30天内,将在 Rhythm 网站上提供网络广播的重播。 关于节奏 Rhythm 公司是一家后期生物制药公司,主要致力于开发和商业化治疗罕见的遗传性肥胖疾病的疗法。2019年8月,公司宣布其 MC4R 激动剂 setmelotide 在患有 POMC 缺陷肥胖和 LEPR 缺陷肥胖的人群中的关键3期临床试验的阳性结果,并于2020年3月完成首次向 FDA 提交的滚动 NDA 申报。Rhythm 还在评估在 Bardet-Biedl 和 Alstr ö m 综合症患者的关键第3阶段试验中使用黑素来减少饥饿和体重的效果,预期这项试验的顶级数据将在2020年第四季度或2021年第一季度初公布。Rhythm 正在利用 Rhythm 引擎,包括第二阶段的篮子研究, TEMPO 注册, GO-ID 基因分型研究和摆脱罕见的肥胖项目,以提高了解,诊断和潜在的治疗罕见的遗传疾病的肥胖。对于医疗保健专业人员,请访问 www.UNCommonObesity.com 了解更多信息。如需更多信息,请访问 www.LEADforRareObesity.com 。公司总部设在马萨诸塞州的波士顿。 前瞻性陈述 本新闻稿包含前瞻性陈述的含义是1995年私人证券诉讼改革法案。本新闻稿中包含的与历史事实无关的所有陈述均应视为前瞻性陈述,包括但不限于关于黑素肽的潜在、安全性、有效性、法规和临床进展、预期发布一线临床试验数据的时间安排的陈述。以及参加即将举行的专题介绍和会议。使用“预期”、“预期”、“相信”、“可能”、“意愿”等词语的陈述以及类似术语也是前瞻性陈述。该等陈述既不是承诺亦不是保证,但涉及已知及未知的风险、不明朗因素及其他可能导致我们的实际业绩、表现或成就与前瞻性陈述所表达或隐含的任何未来业绩、表现或成就有重大差异的重要因素,包括但不限于我们管理转型的影响、我们在临床试验中招募患者的能力、临床试验的设计和结果、竞争的影响、实现或获得必要监管批准的能力、与数据分析和报告相关的风险、我们的流动性和开支、COVID-19大流行对我们的业务和运营的影响,包括我们的临床前研究、临床试验和商业化前景以及一般经济状况,以及我们在截止2020年3月31日的季度10-Q 季报中“风险因素”标题下讨论的其他重要因素,以及我们向证券交易委员会提交的其他文件。除法律要求外,我们不承担任何义务对本新闻稿所载的前瞻性陈述进行任何修订,或对其进行更新,以反映本新闻稿发布日期后发生的事件或情况,无论是由于新信息、未来发展或其他原因。 公司联系人: David Connolly 投资者关系及企业传讯总监 Rhythm Pharmaceuticals , Inc . 857-264-4280 dconnolly @ ordinartx.com 投资者联系方式: Hannah Deresie wicz 斯特恩投资者关系公司. 212-362-1200 汉娜。deresie wicz @ sterr.com 媒体联系人: Adam Daley Berry & Company 公共关系 212-253-8881 adaley @ berryypr.com

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文